Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06384443
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2024-04-22
Brief Title:
Proton Pump Inhibitors in Cirrhotic Patients
Sponsor:
National Liver Institute Egypt
Organization:
National Liver Institute Egypt
Study Overview
Official Title:
Inappropriate Use of Proton Pump Inhibitors in Patients With Liver Cirrhosis
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Proton pump inhibitors PPIs inappropriate use in patients with cirrhosis presents a significant clinical challenge This study evaluates overprescription and misuse of PPIs in cirrhotic patients The patterns of use of PPIs will be classified into two groups based on adherence to the proven indications Group A Inappropriate use of PPI Group B Appropriate use of PPI We will estimate the prevalence of PPI misuse in cirrhotics and correlate it with different factors
Detailed Description:
The inappropriate use of PPIs in cirrhosis patients is a growing concern Evidence supporting the use of PPIs in cirrhosis-related conditions is limited Several adverse outcomes have been linked to PPI use in cirrhosis including an increased risk of spontaneous bacterial peritonitis and hepatic encephalopathy
The study aimed to assess the appropriateness of prescribing PPIs to patients with cirrhosis examining its impact on prescribing practices and identifying associated factors
in this observational descriptive cross-sectional study cirrhotic patients receiving proton pump inhibitors will be included in the study Enrolled patients will classified according to the indication for PPI administration Group A Inappropriate use of PPI Group B Appropriate use of PPI Use of PPI will be considered inappropriate when prescribed without approved indication or used for a prolonged period beyond the recommended duration The prevalence of PPI misuse in cirrhotics will be estimated and multivariate analyses will be conducted in order to identify independent predictors of inappropriate use of PPI
The study aimed to assess the appropriateness of prescribing PPIs to patients with cirrhosis examining its impact on prescribing practices and identifying associated factors
in this observational descriptive cross-sectional study cirrhotic patients receiving proton pump inhibitors will be included in the study Enrolled patients will classified according to the indication for PPI administration Group A Inappropriate use of PPI Group B Appropriate use of PPI Use of PPI will be considered inappropriate when prescribed without approved indication or used for a prolonged period beyond the recommended duration The prevalence of PPI misuse in cirrhotics will be estimated and multivariate analyses will be conducted in order to identify independent predictors of inappropriate use of PPI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None